Spironolactone

"Spironolactone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)

Descriptor ID	D013148
MeSH Number(s)	D02.540.679 D04.210.500.745.745.855
Concept/Terms	Spironolactone Spironolactone Spirolactone Veroshpiron Verospirone Spiractin Spiractin Spirobeta Spirobeta Spirogamma Spirogamma Spirolang Spirolang Spirono-Isis Spirono-Isis Spirono Isis Spironone Spironone Spirospare Spirospare Aldactone Aldactone Verospiron Verospiron Aldactone A Aldactone A Aquareduct Aquareduct Duraspiron Duraspiron Espironolactona Alter Espironolactona Alter Espironolactona Mundogen Espironolactona Mundogen Flumach Flumach Frumikal Frumikal Jenaspiron Jenaspiron Novo-Spiroton Novo-Spiroton Novo Spiroton NovoSpiroton Practon Practon SC-9420 SC-9420 SC 9420 SC9420 Spiro L.U.T. Spiro L.U.T. Spiro Von Ct Spiro Von Ct Ct, Spiro Von Von Ct, Spiro

Below are MeSH descriptors whose meaning is more general than "Spironolactone".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Lactones [D02.540]
Spironolactone [D02.540.679]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Pregnanes [D04.210.500.745]
Pregnenes [D04.210.500.745.745]
Spironolactone [D04.210.500.745.745.855]

Below are MeSH descriptors whose meaning is related to "Spironolactone".

Below are MeSH descriptors whose meaning is more specific than "Spironolactone".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Spironolactone" by people in this website by year, and whether "Spironolactone" was a major or minor topic of these publications.

Bar chart showing 11 publications over 9 distinct years, with a maximum of 3 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	0	1
2011	0	1	1
2015	1	0	1
2016	1	0	1
2018	1	0	1
2020	0	1	1
2021	2	1	3
2022	1	0	1
2024	0	1	1

Below are the most recent publications written about "Spironolactone" by people in Profiles.

Lam K, Kraft WK, Zhan T, Lam E. Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial. Clin Transl Sci. 2024 Mar; 17(3):e13721.

View in: PubMed
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, Gonz?lez A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2022 02 16; 8(2):149-156.

View in: PubMed
Naccarelli GV, Filippone EJ, Foy A. Do Mineralocorticoid Receptor Antagonists Suppress Atrial?Fibrillation/Flutter? J Am Coll Cardiol. 2021 07 13; 78(2):153-155.

View in: PubMed
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, Gonz?lez A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021 02 11; 42(6):684-696.

View in: PubMed
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, D?ez J, Edelmann F, Girerd N, Gonz?lez A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC Heart Fail. 2021 04; 9(4):268-277.

View in: PubMed
Kalra R, Gupta K, Sheets R, Aryal S, Ebrahimi A, Rajapreyar I, Cribbs MG, Booker OJ, Prabhu SD, Bajaj NS. Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). Am J Cardiol. 2020 08 15; 129:46-52.

View in: PubMed
Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina. 2018 May; 38(5):962-969.

View in: PubMed
Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. Retina. 2016 Mar; 36(3):611-8.

View in: PubMed
Salz DA, Pitcher JD, Hsu J, Regillo CD, Fineman MS, Elliott KS, Vander JF, Fischer DH, Spirn MJ. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015 Apr; 46(4):439-44.

View in: PubMed
Lazic T, Li Q, Frank M, Uitto J, Zhou LH. Extending the phenotypic spectrum of keratitis-ichthyosis-deafness syndrome: report of a patient with GJB2 (G12R) Connexin 26 mutation and unusual clinical findings. Pediatr Dermatol. 2012 May-Jun; 29(3):349-57.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement